Influenza, SARS-CoV-2 and RSV activity in EU/EEA Member States continue to decrease or remain stable at low levels. Cases, including severe infections, can still occur and it therefore remains essential to continue testing patients presenting with severe acute respiratory symptoms in order to guide treatment and inform epidemiological assessments.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 28 April - 4 May 2024 and includes updates on cholera, MERS-CoV, SARS-CoV-2, an overview of respiratory virus epidemiology in the EU/EEA, highly pathogenic avian influenza A(H5N1) in cattle and a related human case, Crimean-Congo haemorrhagic fever, and Lassa fever.
Resistance of Salmonella and Campylobacter bacteria to commonly used antimicrobials continues to be observed frequently in humans and animals, according to a report issued today by EFSA and ECDC.
This is a summary of the fourth joint inter-agency report on integrated analysis of antimicrobial consumption and occurrence of antimicrobial resistance in bacteria from humans and food-producing animals in the European Union (JIACRA IV – 2019–2021).
This report provides an integrated analysis of relationships between antimicrobial consumption in humans and food- producing animals and the occurrence of antimicrobial resistance in bacteria from humans and food- producing animals, respectively.
The food-borne infections listeriosis and shigatoxigenic Escherichia coli are increasing in the EU/EEA and were in 2022 at levels higher than before the COVID-19 pandemic.
For 2022, 29 European Union/European Economic Area (EU/EEA) countries reported 8 565 confirmed cases of Shiga toxin-producing Escherichia coli (STEC) infection.